Influence of radical prostatectomy for prostate cancer on work status and working life 3 years after surgery
- 331 Downloads
The purpose of this study is to study the influence of radical prostatectomy (RP) for prostate cancer on work status and working life in men 3 years after surgery.
In a prospective, questionnaire-based study on adverse effects after RP, 330 prostate cancer (PCa) patients who had been active in the workforce before RP described their work status 3 years after having surgery. We dichotomized their postoperative work status into “unchanged or increased” versus “reduced.” The participants also reported whether their working life was influenced by the PCa trajectory to no, some, or a great extent. Univariate and multiple logistic regression models were established with sociodemographic and clinical characteristics as independent variables and “work status” or “influence of PCa trajectory on working life” as dependent variables.
Twenty-five percent of the participants had retired. Of the remaining participants, approximately 20 % had a reduced work status, which in the multivariate analyses was significantly associated with increasing age. One third of the men still active in the workforce considered the PCa to negatively influence their working life. This was independently associated with bother related to urinary leakage, fatigue, and having undergone additional oncological therapy (pelvic radiotherapy and/or hormone treatment).
Though RP does not affect work status in most men, approximately one third of them experience problems in their working life due to adverse effects related to RP and/or additional post-RP anti-cancer therapy.
Implications for Cancer Survivors
Most PCa survivors can expect to remain in the workforce for at least 3 years after RP, but for some, persistent adverse effects after RP and /or additional anti-cancer treatment negatively affect their working life. Pre-RP counseling of men within the workforce should cover possible post-RP changes concerning work status and working life.
KeywordsProstate cancer Radical prostatectomy Work participation Adverse effects
Conflict of interest
The authors declare that they have no conflict of interest.
The Norwegian Cancer Society funded the study.
- 3.Guidelines on prostate cancer. http://www.uroweb.org/gls/pdf/08%20Prostate%20Cancer_LR%20March%2013th%202012.pdf.2013
- 5.Stensvold A, Dahl AA, Brennhovd B, Smastuen MC, Fossa SD, Lilleby W, et al. Bother problems in prostate cancer patients after curative treatment. Urol Oncol 2012 Feb 16Google Scholar
- 6.Dahl S, Steinsvik EA, Dahl AA, Loge JH, Cvancarova M, Fossa SD. Return to work and sick leave after radical prostatectomy: a prospective clinical study. Acta Oncol 2013 Nov 6.Google Scholar
- 7.Steinsvik EA, Axcrona K, Dahl AA, Eri LM, Stensvold A, Fossa SD. Can sexual bother after radical prostatectomy be predicted preoperatively? Findings from a prospective national study of the relation between sexual function, activity and bother. BJU Int. 2012;109(9):1366–74.CrossRefPubMedGoogle Scholar
- 12.Statistics Norway. Levekårsundersøkelsen 2002. 2014. Ref Type: Unpublished WorkGoogle Scholar
- 13.Gandek B, Ware JE, Aaronson NK, Apolone G, Bjorner JB, Brazier JE, et al. Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. Int Qual Life Assess J Clin Epidemiol. 1998;51(11):1171–8.Google Scholar
- 15.Nordby P, Nerland SM, Næsheim H. Yrkesaktivitet blant eldre før og etter pensjonsreformen. Statistics Norway 2014Google Scholar
- 16.Wold M.G, Håland I. Eldre i arbeidslivet. Statistics Norway 2014Google Scholar
- 23.Duijts S, Egmond M, Spelten E, van Muijen P, Anema J, van der Beek A. Physical and psychosocial problems in cancer survivors beyond return to work: a systematic review. Psycho-Oncology. 2013;22:327–8.Google Scholar
- 26.Resnick MJ, Barocas DA, Morgans AK, Phillips SE, Chen VW, Cooperberg MR, et al. Contemporary prevalence of pretreatment urinary, sexual, hormonal, and bowel dysfunction: defining the population at risk for harms of prostate cancer treatment. Cancer 2014 Feb 7.Google Scholar
- 34.Iversen P, Mcleod DG, See WA, Morris T, Armstrong J, Wirth MP. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. BJU Int. 2010;105(8):1074–81.CrossRefPubMedGoogle Scholar